Clinical TrialJul 22, 2026, 07:01 AM
NRX Pharma Subsidiary's Clinical Trial Proposal Selected by DARPA
AI Summary
NRX Pharmaceuticals announced that its subsidiary, NRx Defense Systems (NRXD), received notification from DARPA that its clinical trial proposal, SPARC-TMS, was selected for negotiation of a potential award. The SPARC-TMS trial, a phase 2/3 study approved by the FDA, aims to evaluate robotic-enabled Transcranial Magnetic Stimulation combined with NRX-101 for depression remission. While this is a significant step, the selection does not guarantee an award and is subject to successful negotiation of definitive terms.
Key Highlights
- NRX Defense Systems (NRXD) clinical trial proposal selected by DARPA for potential award negotiation.
- NRXD, a subsidiary of NRX Pharmaceuticals, was incorporated in April 2026.
- The SPARC-TMS trial is a phase 2/3 trial approved by the US FDA.
- Trial aims to demonstrate efficacy of robotic-enabled TMS combined with NRX-101 for depression remission.
- NRX-101 previously received FDA Breakthrough Therapy Designation.
- Study planned at Harvard Mclean, HOPE Therapeutics, and military treatment facilities.
- Selection for negotiation does not constitute a notice of award or commitment.
Price Impact
More from NRXP